Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

BACKGROUND: Acute myeloid leukemia (AML) is a type of leukemia in adults with a high mortality rate and poor prognosis. Although targeted therapeutics, chemotherapy, and hematopoietic stem cell transplantation can improve the prognosis, the recurrence rate is still high, with a 5-year survival rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Eunhee, Lee, Shinai, Park, Sumyeong, Son, Yong-Gyu, Yoo, Jiseon, Koh, Youngil, Shin, Dong-Yeop, Lim, Yangmi, Won, Jonghwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582864/
https://www.ncbi.nlm.nih.gov/pubmed/37848261
http://dx.doi.org/10.1136/jitc-2023-007494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582864/
https://www.ncbi.nlm.nih.gov/pubmed/37848261
http://dx.doi.org/10.1136/jitc-2023-007494

Ejemplares similares